solid tumor
Conditions
Interventions
trial group:monotherapy or combination therapy with Iparomlimab and Tuvonralimab
Sponsors
Shandong Provincial Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. Late stage solid tumors diagnosed by pathology are not limited to previous anti-tumor treatment plans; According to the RECIST v1.1 standard, there must be at least one measurable lesion; 4. ECOG is 0 or 1; 5. Expected survival time exceeds 3 months; 6. Plan to receive monotherapy or combination therapy with Iparomlimab and Tuvonralimab for anti-tumor treatment; 7. Voluntarily join the study, sign an informed consent form, have good compliance, and be able to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Past or current autoimmune diseases, interstitial lung disease, or other diseases that require long-term use of systemic corticosteroids (>10 mg/day prednisone) or other immunosuppressive drugs; 2. Previous immunotherapy has resulted in grade 3 or 4 immune related adverse events (irAEs); 3. Known pregnant or lactating women. 4. Researchers evaluate those who are not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safty; | — |
Secondary
| Measure | Time frame |
|---|---|
| rwPFS;TTF;TFST;Overall survival; | — |
Countries
China
Contacts
Public ContactJie Liu
Shandong Provincial Public Health Clinical Center
Outcome results
None listed